479 related articles for article (PubMed ID: 21459217)
1. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.
Holz FG; Amoaku W; Donate J; Guymer RH; Kellner U; Schlingemann RO; Weichselberger A; Staurenghi G;
Ophthalmology; 2011 Apr; 118(4):663-71. PubMed ID: 21459217
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
Schmidt-Erfurth U; Eldem B; Guymer R; Korobelnik JF; Schlingemann RO; Axer-Siegel R; Wiedemann P; Simader C; Gekkieva M; Weichselberger A;
Ophthalmology; 2011 May; 118(5):831-9. PubMed ID: 21146229
[TBL] [Abstract][Full Text] [Related]
3. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
4. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy.
Arias L; Caminal JM; Badia MB; Rubio MJ; Catala J; Pujol O
Retina; 2010; 30(10):1601-8. PubMed ID: 21060271
[TBL] [Abstract][Full Text] [Related]
6. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
7. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab for neovascular age-related macular degeneration in China.
Li X; Hu Y; Sun X; Zhang J; Zhang M;
Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
[TBL] [Abstract][Full Text] [Related]
9. Determinants of fixation in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
Mathew R; Pearce E; Sivaprasad S
Am J Ophthalmol; 2012 Mar; 153(3):490-496.e1. PubMed ID: 22071230
[TBL] [Abstract][Full Text] [Related]
10. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study.
Charbel Issa P; Finger RP; Kruse K; Baumüller S; Scholl HP; Holz FG
Am J Ophthalmol; 2011 May; 151(5):876-886.e1. PubMed ID: 21334595
[TBL] [Abstract][Full Text] [Related]
11. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
Barbazetto I; Saroj N; Shapiro H; Wong P; Freund KB
Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
[TBL] [Abstract][Full Text] [Related]
13. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial.
Heier JS; Brown D; Ciulla T; Abraham P; Bankert JM; Chong S; Daniel PE; Kim IK
Ophthalmology; 2011 Jan; 118(1):111-8. PubMed ID: 20678799
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.
Pece A; Isola V; Piermarocchi S; Calori G
Br J Ophthalmol; 2011 Jan; 95(1):56-68. PubMed ID: 20601660
[TBL] [Abstract][Full Text] [Related]
16. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
Dugel PU; Petrarca R; Bennett M; Barak A; Weinberger D; Nau J; Jackson TL
Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
[TBL] [Abstract][Full Text] [Related]
17. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
Park SS; Daftari I; Phillips T; Morse LS
Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy.
Kumar A; Sahni JN; Stangos AN; Campa C; Harding SP
Br J Ophthalmol; 2011 Apr; 95(4):530-3. PubMed ID: 20937739
[TBL] [Abstract][Full Text] [Related]
19. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.
Keane PA; Chang KT; Liakopoulos S; Jivrajka RV; Walsh AC; Sadda SR
Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984
[TBL] [Abstract][Full Text] [Related]
20. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
Brown DM; Campochiaro PA; Bhisitkul RB; Ho AC; Gray S; Saroj N; Adamis AP; Rubio RG; Murahashi WY
Ophthalmology; 2011 Aug; 118(8):1594-602. PubMed ID: 21684606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
